5 Years of Follow-up After Transplant, in Which an Attempt Was Made to Suspend IS, Single Transplant
Conditions
Keywords
Metabolic Syndrome, Liver transplantation, Immunosoppression, Tolerance
Brief summary
Evaluate de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy (tolerant) and in those taking immunosuppressive therapy (non-tolerant).
Detailed description
A retrospective single-center study was conducted aiming to define the incidence of de novo Metabolic Syndrome (MS) in patients who withdraw Immunosoppression (IS) drugs after Liver Transplant (Tolerant-group) compared to these who couldn't wean IS drugs(non-TOL-group).
Interventions
compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
Sponsors
University of Rome Tor Vergata
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
49 Years to 89 Years
Healthy volunteers
No
Inclusion criteria
* single LT recipients with an attempt of IS withdrawal * minimum 5 years follow-up
Exclusion criteria
* Liver transplant combined with other organs * Presence of metabolic syndrome and/or NASH and/or NAFLD as an indication for liver transplantation * Loss of patient to follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| relation between MS development and IS in LT recipients | 5 years | Evaluate the de novo onset of metabolic syndrome, NAFLD and NASH in liver transplant recipients who have discontinued immunosuppressive therapy (tolerant) and in those who could not withdraw IS (non-tolerant). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| IS withdrawal in LT recipients | 5 years | Evaluate the clinical course of patients undergoing discontinuation of immunosuppressive therapy |
Countries
Italy
Outcome results
None listed